◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Biocon Limited (BIOCON) Revenue 2023–TTM

Name: Biocon Limited (BIOCON) revenue history 2023-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-11-01

Biocon Limited annual revenue for fiscal TTM was ₹172.1 billion, an increase of 2.6% from ₹167.8 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

BIOCON Annual Revenue

Revenue (annual)	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹172.1B	₹167.8B	₹150.5B	₹142.0B	₹109.3B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BIOCON Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹42.9B	₹44.8B	₹41.7B	₹42.6B	₹39.1B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

ABBV Revenue — AbbVie
ANTHEM Revenue — Anthem Biosciences Limited
6160 Revenue — BeOne Medicines AG
AMGN Revenue — Amgen
GILD Revenue — Gilead Sciences
VRTX Revenue — Vertex Pharmaceuticals

More BIOCON metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All BIOCON financial statements → Interactive BIOCON charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.